← Metformin × all-cause mortality

SynthesisBMC infectious diseases2019

Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review.

Xinyu Yu et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2019

Randomised comparison

Probably lowered glycemic control

−76%−82% to −68%

Bigger than 8 in 10 for glycemic control

As reported

RR 0.24, 95% CI 0.18–0.32

Randomised comparison

Probably reduced deaths

−53%−73% to −17%

Bigger than 9 in 10 for all-cause mortality

As reported

OR 0.47, 95% CI 0.27–0.83 · the paper's word: All-cause mortality

Randomised comparison

Probably reduced deaths

−53%−73% to −17%

Bigger than 9 in 10 for all-cause mortality

As reported

OR 0.47, 95% CI 0.27–0.83 · the paper's word: All-cause mortality

Randomised comparison

Probably lowered blood pressure

−66%−83% to −33%

Bigger than 9 in 10 on the map

As reported

RR 0.337, 95% CI 0.17–0.67

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with fewer deaths

−53%−73% to −17%

Bigger than 9 in 10 for all-cause mortality

As reported

OR 0.47, 95% CI 0.27–0.83 · the paper's word: All-cause mortality

Correlation, not cause

Went with more deaths

2.7×1.1× to 6.7×

Bigger than almost all for all-cause mortality

As reported

OR 2.72, 95% CI 1.11–6.69 · the paper's word: All-cause mortality

+4 more in the walkthrough ↓

Ten numbers in the abstract

the abstract, start to end

… with a smaller TB mortality (OR, 0.47; 95%CI, 0.27 to 0.83), and a higher probability of sputum culture conversion at 2 months of TB disease (OR, 2.72; 95%CI, 1.11 to 6.69) among …

… without metformin usage 329 Adjusted RR: 0.24 (95%CI, 0.18 to 0.32) …

… the exposure criteria 1514 Adjusted HR: 0.84 (95%CI, 0.74 to 0.96) TB risk …

… patients with cavitary pulmonary TB (OR, 10.8; 95%CI, 1.22 to 95.63) Sex, …

… patients in the non-metformin group (OR, 0.29; 95%CI, 0.14 to 0.95).

… could be limited by metformin usage (OR, 0.47; 95%CI, 0.27 to 0.83), and the …

… could be limited by metformin usage (OR, 0.47; 95%CI, 0.27 to 0.83), and the …

… daily dose of metformin 263 Adjusted RR: 0.337 (95%CI, 0.169 to 0.673) …

… metformin use (prevalence difference, 1.4, 95%CI, -3.7 -6.4%) compared to …

← favours treatmentfavours comparator →
could be chance
All-cause mortality
OR 0.470.27–0.83
All-cause mortality
OR 2.721.11–6.69
Glycemic control
RR 0.240.18–0.32
Pharmacokinetics & dosing
HR 0.840.74–0.96
All-cause mortality
OR 10.81.22–95.6
All-cause mortality
OR 0.290.14–0.95
All-cause mortality
OR 0.470.27–0.83
All-cause mortality
OR 0.470.27–0.83
Blood pressure
RR 0.3370.17–0.67
Adverse events & safety
1.4−3.70 to 6.40
MetforminOther glucose-loweringGlycemic controlBlood pressureAll-cause mortalityAdverse events & safetyPharmacokinetics & dosing

Metformin × all-cause mortalityhelps?one trial

unlikelylikely
0.50not counted

Metformin × adverse events & safetyharms?mixed

unlikelylikely
0.27not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

33 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it

The trial

NCT05215990phase 1/phase 280 enrolled2022
Full record →Abstract, authors, funding and every citing paper · PMID 31623569